Optional callout banner for highlighted news or events
Learn MoreBecoming a well-rounded biopharmaceutical expert starts at a contract development and manufacturing organization (CDMO).
When a pharmaceutical company establishes the formula for a new drug, they will enlist the help of a CDMO to navigate the highly regulated drug development framework required by the FDA. Having a CDMO partner can be a great resource with benefits for bio/pharmaceutical companies to focus their efforts and resources on initiatives that move their company forward.1
According a leading career consultant, CDMOs are an excellent place to start your career1:
Pharmaceutics International, Inc. (Pii) is a US-based, science-driven CDMO with a passion for solving problems. Pii’s Hunt Valley, Maryland, campus includes 70 manufacturing suites with four integrated aseptic filling lines. We offer unparalleled scientific insight and depth of product knowledge to supply high quality dosage forms that enhance the lives of patients worldwide.
Pii has more than 360,000 sq. ft. of operating space. Our cGMP and DEA-registered facilities are state-of-the-art and contain more than 70 manufacturing suites, including containment areas for handling high potency compounds and hormones, dedicated manufacturing suites for oral products (i.e. soft gels) and injectables (i.e. vials, syringes, cartridges), a formulation development center, and ultra-modern analytical and micro laboratories.
Pii wants to tackle the difficult projects that other CDMOs turn away. We can handle early-stage development projects to get clients into the clinic faster and we can scale up these projects to commercial manufacture.
We want to fill out our capacity in all our existing plants and we have technology and capabilities to do so. For instance, we have massive analytical labs with HPLCs as far as the eye can see. And, Pii has the assets to offer contract analytical services, method development and validation, and stability testing. Our in-house analytical capabilities align with our other core development functions so that our scientific team can accelerate timelines and scale up formulations.
As a CDMO, Pii has supported aseptic fill-finish manufacturing since 2006, specializing in NDAs, NCEs, DEA-scheduled products, and most recently, biologics. Pii’s Groninger syringe line supports batch sizes up to 50,000 syringes per day with pre-filled syringe sizes ranging from 1mL through 5mL.
Founded in 1994, Pii has grown from 12 employees to more than 270 scientists and support staff. Pii has a diverse community of scientists who are at the top of their game in lyophilization, analytical development, R&D, product development, aseptic/fill-finish manufacturing, formulation development, and packaging.
Our scientists have extensive experience with small and large molecule compounds, developing and manufacturing complex parenteral drugs, extended-release formulations, non-aqueous injectable drug products, lyophilization, and DEA scheduled drugs.
We are looking for the brightest and most passionate scientists to join our team. At Pii, your research will help us find tomorrow’s cures – join us in changing the world, one drug at a time.
Like what you read? Share with your network: